Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission
RATIONALE: Vaccines made from dendritic cells may help the body build an effective immune response to kill cancer cells.
PURPOSE: This phase I trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with acute myeloid leukemia in complete remission.
|Study Design:||Allocation: Non-Randomized
Primary Purpose: Treatment
|Official Title:||Pilot Study of Therapeutic Vaccination by Leukemic Blasts in Vitro Differentiated Dendritic Cells From Patients With Acute Myelogenous Leukemia in Complete Remission|
- Adverse events at 6 months [ Designated as safety issue: Yes ]
|Study Start Date:||June 2008|
|Primary Completion Date:||May 2011 (Final data collection date for primary outcome measure)|
- Assess the tolerability of autologous dendritic cell vaccine in patients with acute myelogenous leukemia in complete remission.
- Evaluate the emergence of an immune response.
- Determine the relapse rate.
- Assess the occurrence of residual disease.
OUTLINE: Patients receive increasing doses of blastic cells transformed in vitro by autologous dendritic cells (1/3 subcutaneously and 2/3 IV) every 3 weeks for up to 5 doses.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00963521
|Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes|
|Marseille, France, 13273|
|Investigator:||Christian Chabannon, MD, PhD||Institut Paoli-Calmettes|